Developing Country Sales Continue to Drive Growth at Cepheid as China Approves Xpert TB Test | GenomeWeb

NEW YORK (GenomeWeb) — Cepheid's high-burden developing country (HBDC) program — the initiative through which it sells its GeneXpert system and related tuberculosis/drug-resistance test to resource-poor territories at a subsidized, discounted price — continues to serve as an important revenue driver at the company.

The Sunnyvale, Calif.-based MDx firm said last week that its first quarter revenues grew 16 percent year over year to $106.9 million, driven in no small part by 69 percent growth in its HBDC program to $18.3 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.